Volver a Agenda
Session 7: Continuation of Session 6: Results Reporting according to EU Clinical Trials Regulation
Session Chair(s)
Merete Joergensen, MBA, MSC
Clinical Disclosure and Transparency Expert, Merete-J Consulting, Denmark
Robert Paarlberg, MS
Principal, Paarlberg & Associates LLC, United States
In continuation of the Session 6 on Results Reporting via CTIS (EU), Policy 0070 (EU) and PRCI (Canada) this Session aims to provide further information such as visions for future collaboration, and mutual collaboration for ensuring harmonized documents being made available. For the panel discussion central representatives from Regulators in EU and Canada, from sponsor organizations and CROs aims to give ample opportunities for asking questions. Note: Marianne Luzner, Elizabeth Lieu, and Radu Popescu and will be participating virtually
Learning Objective : - Recognize the value and opportunities in visions for increased collaboration and mutual recognition of same documents for disclosure via different platforms
- Express your views on opportunities and challenges in relation to the current experience with Policy 0070 and the PRCI
- Ask your questions and obtain clarification from Regulators and Sponsor organizations
Speaker(s)
Approach to Clinical Trial Transparency & Disclosure is Changing – EMA’s Policy 0070 is a Large Contributor. / Panelist.
Sr. Transparency Specialist, Certara, Canada
Redacted Document Challenges. / Panelist.
Associate Director, Clinical Trial Transparency & Disclosure, Kura Oncology, United States
Panel Discussion: Addressing questions in relation to Requirements, Challenges & Complexities of Submitting Results Summaries, CSR’s via CTIS, Policy 0070 EU, and the PRCI (Canada)
CTIS Transparency Lead, European Medicines Agency, Netherlands
Panel Discussion: Addressing questions in relation to Requirements, Challenges & Complexities of Submitting Results Summaries, CSR’s via CTIS, Policy 0070 EU, and the PRCI (Canada)
Scientific Administrator, European Medicines Agency, Netherlands
Panel Discussion: Addressing questions in relation to Requirements, Challenges & Complexities of Submitting Results Summaries, CSR’s via CTIS, Policy 0070 EU, and the PRCI (Canada)
Senior Regulatory Affairs Officer, Health Canada, Canada
Panel Discussion: Addressing questions in relation to Requirements, Challenges & Complexities of Submitting Results Summaries, CSR’s via CTIS, Policy 0070 EU, and the PRCI (Canada)
Assessor, Dept of Clinical Trials, Federal Office for Safety in Health Care, AGES, Austria
¿Tiene una cuenta?